First, in trials that resulted in FDA approval since 2014, the participation of females has consistently trended toward general parity (although notable differences between therapeutic areas still persist)
In clinical practice, it is common to see frustrated patients who tried oral or sublingual versions without noticing any changes in body composition, energy levels, or sleep quality
Promoting the use of such compounds for healing and performance enhancement is unethical and banned by the US Anti-Doping Agency
The STEP 5 trial found that 92.8% of participants completed the full two-year study, indicating excellent long-term tolerability
This doesn't indicate danger, just absence of data
USADA's advisory on sermorelin confirms its prohibition due to its ability to elevate endogenous GH production